Burt Adelman

USPTO Granted Patents = 14 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 42(Granted Patents)

Company Filing History:

10 out of 1,177

Takeda Pharmaceutical Company Limited

Years Active: 2010-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12442824 - Assays for determining plasma kallikrein system biomarkers (2025-10-14),

2. 12415866 - Monoclonal antibody inhibitor of Factor XIIa (2025-09-16),

3. 12384854 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2025-08-12),

4. 12240918 - Bispecific antibodies against plasma kallikrein and factor XII (2025-03-04),

5. 12061206 - Diagnosis and treatment of autoimmune diseases (2024-08-13),

6. 11390687 - Bispecific antibodies against plasma kallikrein and Factor XII (2022-07-19),

7. 11372002 - Assays for determining plasma kallikrein system biomarkers (2022-06-28),

8. 11286307 - Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack (2022-03-29),

9. 11156612 - Methods of determining levels of cleaved and/or intact kininogen (2021-10-26),

10. 11084884 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2021-08-10),

11. 10913802 - Monoclonal antibody inhibitor of factor XIIA (2021-02-09),

12. 10648990 - Diagnosis and treatment of autoimmune diseases (2020-05-12),

13. 10101344 - Diagnosis and treatment of autoimmune diseases (2018-10-16),

14. 7662921 - Methods of treating viral disorders (2010-02-16),

Title: Burt Adelman: Innovator in Biomedical Research

Introduction

Burt Adelman is a prominent inventor based in Concord, MA (US), known for his significant contributions to biomedical research. With a total of 14 patents to his name, he has made substantial advancements in the field of medical diagnostics and treatment.

Latest Patents

Among his latest patents are innovative methods and assays for determining the activation level of the plasma kallikrein system. These assays are crucial for assessing the activity of plasma kallikrein modulators. Another notable patent is for a monoclonal antibody inhibitor of Factor XIIa, which includes anti-Factor XIIa antibodies and methods for treating diseases associated with Factor XII. This includes conditions related to contact system activation, plasma prekallikrein signaling, hereditary angioedema, and ocular diseases.

Career Highlights

Burt has worked with notable companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Dyax Corporation. His work in these organizations has been instrumental in developing therapies that address critical health issues.

Collaborations

Throughout his career, Burt has collaborated with esteemed colleagues such as Daniel J Sexton and Andrew Nixon. These partnerships have further enhanced his research and innovation efforts.

Conclusion

Burt Adelman's contributions to biomedical research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to impact the development of treatments for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.